Prostate Cancer Clinical Trial
Official title:
A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer
Background:
- Advanced prostate cancer is treated with surgery or drugs that lower the levels of
androgens (male hormones) in the body. However, some cancers become resistant to this
treatment. These types of cancers are known as castration-resistant prostate cancers.
- Interfering with the growth of blood vessels that feed tumors can slow prostate cancer
growth. Trebananib (AMG 386), a new anticancer drug, targets the blood vessels that feed
tumors. It has been tested for different types of cancer, but not for prostate cancer.
Researchers want to see if AMG 386 can slow disease progression in men with
castration-resistant prostate cancer. AMG 386 will be given with abiraterone and
prednisone, two drugs that are also used to treat advanced prostate cancer.
Objectives:
- To test the safety and effectiveness of AMG 386 with abiraterone for castration-resistant
prostate cancer.
Eligibility:
- Men at least 18 years of age with castration-resistant prostate cancer.
Design:
- Participants will be screened with a physical exam, medical history, and imaging
studies. Blood and urine samples will also be collected.
- Participants will be separated into two groups.
- The first group will have AMG 386 once per week for a total of four doses during a
28-day cycle. They will also take abiraterone once a day and prednisone twice a day,
every day of the cycle.
- The second group will not have AMG 386. They will take abiraterone once a day and
prednisone twice a day, every day of the 28-day cycle.
- Treatment will be monitored with frequent blood tests and imaging studies.
- Participants will continue to take the study drugs as long as the disease does not
progress and there are no severe side effects.
Background:
- Inhibition of angiogenesis, either as a stand-alone approach or in combination with
chemotherapy, has demonstrable antitumor efficacy against castration-resistant prostate
cancer (CRPC) and there are several antiangiogenic agents that are now in clinical
trials in this population of patients.
- AMG 386 is a novel peptide-Fc fusion protein. The molecule is a non-glycosylated
homodimer engineered by fusing an Immunoglobulin gamma-1 heavy chain constant region,
partial (IgG1 Fc) domain to 4 copies of an anti-angiopoietin 2 (Ang2) peptide. AMG 386
sequesters Ang1 and Ang2, thereby preventing their interaction with Tie2 and inhibiting
tumor endothelial cell (EC) proliferation and tumor growth.
- Abiraterone acetate is a small molecule that irreversibly inhibits Cytochrome P450 17A1
(CYP17), a rate-limiting enzyme in androgen biosynthesis, to block residual androgen
synthesis in the adrenal gland and tumor cells.
- Previous studies have demonstrated that in vivo alterations of testosterone levels
regulate the expression of vascular endothelial growth factor (VEGF), fibroblast growth
factor (FGF), and angiopoietin family members. Dual targeting of the androgen and
angiogenic axis represents a novel approach as a potential targeted therapy for patients
with metastatic castration-resistant prostate cancer (CRPC).
Objectives:
-To estimate the treatment effect as measured by progression free survival (PFS) in patients
treated with AMG 386 plus abiraterone/prednisone relative to abiraterone/prednisone alone.
Eligibility:
-Patients with progressive, metastatic CRPC with radiographic evidence of progression after
primary therapy (surgery or radiotherapy) and adequate androgen deprivation therapy.
Design:
- This is an open-label, randomized, phase II multicenter trial with a two-part design and
a planned accrual of 88 patients.
- An initial run-in phase of AMG 386 will be conducted with 15mg/kg weekly escalating to
30mg/kg weekly to establish the MTD. The decision on declaration of a safe and tolerable
dose during this run-in phase will lead to the second part of the study consisting of a
randomized comparison of abiraterone/prednisone plus AMG 386 (at the established maximum
tolerated dose (MTD)) vs. abiraterone/prednisone alone.
- AMG 386 will be administered intravenously every week, on days 1, 8, 15 and 22 of each
28-day cycle. Abiraterone acetate will be self-administered once daily by mouth and
prednisone will be self-administered by mouth either twice per day at 5 mg per dose or
once per day at 10 mg per dose as the patient prefers.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05613023 -
A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT
|
Phase 3 | |
Recruiting |
NCT05540392 -
An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues
|
Phase 1/Phase 2 | |
Recruiting |
NCT05156424 -
A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT03177759 -
Living With Prostate Cancer (LPC)
|
||
Completed |
NCT01331083 -
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT05540782 -
A Study of Cognitive Health in Survivors of Prostate Cancer
|
||
Active, not recruiting |
NCT04742361 -
Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer
|
Phase 3 | |
Completed |
NCT04400656 -
PROState Pathway Embedded Comparative Trial
|
||
Completed |
NCT02282644 -
Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry
|
N/A | |
Recruiting |
NCT06305832 -
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
|
Phase 2 | |
Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
Recruiting |
NCT05761093 -
Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
|
||
Completed |
NCT04838626 -
Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection
|
Phase 2/Phase 3 | |
Recruiting |
NCT03101176 -
Multiparametric Ultrasound Imaging in Prostate Cancer
|
N/A | |
Completed |
NCT03290417 -
Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer
|
N/A | |
Completed |
NCT00341939 -
Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
|
||
Completed |
NCT01497925 -
Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT03679819 -
Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
|
||
Completed |
NCT03554317 -
COMbination of Bipolar Androgen Therapy and Nivolumab
|
Phase 2 | |
Completed |
NCT03271502 -
Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy
|
N/A |